Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. News
Jul 22, 2025 - businesswire.com
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
Jul 21, 2025 - globenewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
iTeos Therapeutics, Inc. Quantitative Score
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
iTeos Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
iTeos Therapeutics, Inc. Financials
Table Compare
Compare ITOS metrics with: | |||
|---|---|---|---|
Earnings & Growth | ITOS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ITOS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ITOS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ITOS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
iTeos Therapeutics, Inc. Income
iTeos Therapeutics, Inc. Balance Sheet
iTeos Therapeutics, Inc. Cash Flow
iTeos Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
iTeos Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Michel Detheux Ph.D. | President, Chief Executive Officer & Director |
| Dr. David Feltquate M.D., Ph.D. | Chief Medical Officer |
| Mr. Matthew A. Call M.B.A. | Chief Operating Officer |
| Mr. Matthew Gall | Chief Financial Officer |
| Mr. Philippe Brantegem | Chief People Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Michel Detheux Ph.D. | President, Chief Executive Officer & Director | 1967 | 1.12M | |
| Dr. David Feltquate M.D., Ph.D. | Chief Medical Officer | 774.44K | ||
| Mr. Matthew A. Call M.B.A. | Chief Operating Officer | Male | 1973 | 725.48K |
| Mr. Matthew Gall | Chief Financial Officer | Male | 1977 | 648K |
| Mr. Philippe Brantegem | Chief People Officer | Male | -- |
iTeos Therapeutics, Inc. Insider Trades
| Date | 10 Jun |
| Name | Detheux Michel |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 8400 |
| Date | 9 Jun |
| Name | Detheux Michel |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 8400 |
| Date | 9 Jun |
| Name | Detheux Michel |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 43882 |
| Date | 9 Jun |
| Name | Detheux Michel |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 43882 |
| Date | 10 Jun |
| Name | Detheux Michel |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 8400 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 10 Jun | Detheux Michel | Chief Executive Officer | Acquired | M-Exempt | 8400 |
| 9 Jun | Detheux Michel | Chief Executive Officer | Disposed | S-Sale | 8400 |
| 9 Jun | Detheux Michel | Chief Executive Officer | Acquired | M-Exempt | 43882 |
| 9 Jun | Detheux Michel | Chief Executive Officer | Disposed | S-Sale | 43882 |
| 10 Jun | Detheux Michel | Chief Executive Officer | Disposed | S-Sale | 8400 |